James L. Holly, M.D.

An Example of Value-Based Payment:
Chronic Care Management
By James L Holly, MD
Your Life Your Health
The Examiner
October 15, 2015

Value-based Payments are expected to focus more on outcomes – improvement in health – than process – doing "things" to or for patients. For instance value-based payments will focus more on whether patients with diabetes' treatments are resulting in improved care rather than just whether patients with diabetes are receiving certain tests.

To promote this change, Health and Human Services (HHS) is designing new programs for payment which focus on outcomes even when they measure a process. One of those is the new Chronic Care Management (CCM) program. If patients who are treated through fee-for- service Medicare, as opposed to Medicare Advantage, and if healthcare providers can meet the rigorous standards, they can participate in the CCM program and be paid for it.


The Chronic Care Management payment is offered by CMS for the care of patients who have more than two chronic conditions and who are contacted each month for complex care management. The contact must result in an aggregate of 20 minutes of time spend in counseling with the patient by telephone or in person including time spent preparing a plan of care and treatment plan.

It is expected that this program will reduce the utilization of other services and decrease the cost of care for patients on Medicare while improving the quality of care they are receiving. The difficulty for providers is that the requires for payment are rigorous and the potential for healthcare providers being audit to determine if they are meeting the standards of care required is significant.

To participate in this program and to make sure that we comply with all standards, SETMA is designing a clinic decision support tool for documentation and auditing of the requirements. The following is the beginning of a tutorial for SETMA's preparation for this task which includes documentation for:

- 1. Performed to prove that the monthly contact with patients has been completed
- 2. Documented -- to prove that the patients included in the program meet all standards
- 3. Compared each patient is compared to prove that exclusions are met, such as nursing home admission, home healthcare and transitions of care charges being submitted during same period.
- 4. Audited -- to prove to ourselves that all elements of the Chronic Care Management are being done and to be prepared to prove that all elements have consistently been met if we are audited.
- 5. Patient agreement for being involved in the CCM program.

The Chronic Care Management documentation will be launched from SETMA's AAA Home Template as seen below outlined in green:



The CCM is found at the link surround in green above. The Chronic Care Management Master template is shown below. It includes:


1. Primary and Secondary Insurance Designation -- The primary insurance will be Medicare Fee-for-Service. Because the patient will be responsible for the 20% which Medicare does not pay and because many of the patients who need this service cannot afford to pay their part which is \$8.60, it is important for us to know that they are insurance for this to be paid. Medicare doses not allow providers simply to "forgive" the 20% required payment. In order to excuse patients from paying that amount, Medicare requires that three, registered

letters be sent to the patient, requesting payment. For the Chronic Care Management services, the patient's 20% is less than the cost of the collection-effort requirement.


- 2. Patient Status in regard to CCM participation
- 3. Primary Care Provider and Designated CCM contact
- 4. Time Tracing function to document time spent monthly on CCM
- 5. Patient's Current Chronic Problems
- 6. Tracked Problems and whether or not they are currently being tracked.
- 7. Current Medications and whether or not they have been reconciled
- 8. Current Allergies
- 9. Referrals
- 10. Appointment History and Upcoming Appointments.

	Chronic Ca	are Manage	ement			
Patient Larry QTest		Primary Insurance	H		Return	
OB 09/01/1959		Secondary Insurance			Print	
Marie Landing Control		Supplied J. Hospitalis.				
atient Status					Send to NextMD	
Currently active in CCM?	EYON	Primary Care Provide	r H	olly, James L.	Time Tracking - Today	
CCM Consent completed?			Patient	s Other Providers	Date Subje	
	200140045	Designated CCM Con				
		Designated CCM Con	tact	() -	41.1	
Enrolled in NextMD?	Yes		100	305	•	
	Medical Home Co.	ord Review	Pre-Visit/Prever	tive Screen		
stient's Current Chronic Proble		Tracked Prob			Currently tracking?	
Diagnosis Pancreatic cancer	1.4		100			
Lipid metabolism disorder		Cardio Dise		cardial infarction	• Y C N	
Depression due to dementia	1	CHF Depressio	- Inches	ngestive heart failure)	OYCN OYCN	
COPD (chronic obstructive puln disease) with chronic bronchiti		Diabetes	-	s 1.5, managed as type 2	GYCN	
Diabetes 1.5, managed as type		COPD/Asth		thronic obstructive pulmonal	GYCN	
Tourette's disease Compression fracture of spine	1	Hyperlipider	mia Lipid me	tabolism disorder	G Y C N	
Discharge from ear	- 1	Hypertens	CONTRACTOR DESCRIPTION AND ADDRESS OF THE PERSON NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRACTOR NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRACTOR NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRACTOR NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRACTOR NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRACTOR NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRACTOR NAMED IN COLU	59000	@ Y C N	
10 Both parents smoke 11 Testosterone 17-beta-dehydrog	nenase I	Other	Dementi		⊕ Y C N	
deficiency	enase /	Other	Hyperur	icemia	RYCN	
rrent Medications (Double-clic rand Name BLFY	Generic Name ARPIPRAZOLE ASPIRIN		Dose 2 mg 81 mg	Sig Desc take 2.5 by oral route once inject by Subcutaneous rou	Reconcile	
ASPRIN FC		CALCIUM	10 mg	take 1 tablet (10MG) by ora	route every day at bedtime a	
	AIURVASIAIN					
LIPITOR			50 mg	needed take 2 capsule by prai route	2 times every day	
LIPITOR DELEBREX	CELECOXIB CELECOXIB		50 mg 50 mg	needed take 2 capsule by oral route take 2 capsule by oral route		
PITOR ELEBREX ELEBREX YDROCODONE-ACETAMINOPHEN	CELECOXIB CELECOXIB HYDROCODONE	ACETAMNOPHEN	50 mg 5 mg-500 mg	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route	2 times every day every 6 hours as needed for pa	
Pitor Elebrex Elebrex Tydrocodone-acetamnophen	CELECOXIB CELECOXIB HYDROCODONE	VACETAMINOPHEN VACETAMINOPHEN	50 mg 5 mg-500 mg	take 2 capsule by oral route take 2 capsule by oral route	2 times every day every 6 hours as needed for pa	
LPITOR CELEBREX CELEBREX HYDROCODONE-ACETAMINOPHEN HYDROCODONE-ACETAMINOPHEN	CELECOXIB CELECOXIB HYDROCODONE		50 mg 5 mg-500 mg	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route	2 times every day every 6 hours as needed for pa	
PITOR ELEBREX ELEBREX YDROCODONE-ACETAMINOPHEN YDROCODONE-ACETAMINOPHEN	CELECOXB CELECOXIB HYDROCODONE HYDROCODONE		50 mg 5 mg-500 mg	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route	2 times every day very 6 hours as needed for pr very 8 hours as needed	
PITOR ELEBREX ELEBREX YOROCODONE-ACETAMINOPHEN YOROCODONE-ACETAMINOPHEN Internal Allergies (Double-click to	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE O Add/Edit)	Referrals Ordered Sta	50 mg 5 mg-500 mg 10 mg-300 mg	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of tablet 1 tablet 1 tablet by oral route of tablet 1 tablet by oral route of tablet 1 tablet	2 times every day very 6 hours as needed for pe very 8 hours as needed	
PETOR ELEBREX ELEBREX YOROCODONE-ACETAMINOPHEN YOROCODONE-ACETAMINOPHEN Internal Allergies (Double-click to dergy Date O KNOWN DRUG 01/1	CELECOXB CELECOXB HYDROCODONE HYDROCODONE	Referrals Ordered States Display 2015 Description	50 mg 5 mg-500 mg 10 mg-300 mg	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route e take 1 tablet by oral route e take 1 tablet by oral route e Care Coordination Referra Order EEO	2 times every day very 6 hours as needed for pe very 8 hours as needed	
PITOR ELEBREX ELEBREX YOROCODONE-ACETAMINOPHEN YOROCODONE-ACETAMINOPHEN Internal Allergies (Double-click to	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE O Add/Edit)	Referrals Ordered Sta 09:04:2015 occ 07/21/2015 occ	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg Routine	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of table 1 tablet by oral route of tablet 1 ta	2 times every day very 6 hours as needed for pe very 8 hours as needed	
PITOR ELEBREX ELEBREX YOROCODONE-ACETAMINOPHEN YOROCODONE-ACETAMINOPHEN Internal Allergies (Double-click to	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE O Add/Edit)	Referrals	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg situs Prionity ained Routine furmed immediangleted immedia	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of table 1 tablet by oral route of table 1 tablet by oral route of table 1 tablet by oral route of tablet by or	2 times every day very 6 hours as needed for pe very 8 hours as needed	
PETOR ELEBREX ELEBREX YOROCODONE-ACETAMINOPHEN YOROCODONE-ACETAMINOPHEN Internal Allergies (Double-click to dergy Date O KNOWN DRUG 01/1	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE O Add/Edit)	Referrals	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg 10 mg-300 mg Itus Priority ained Routne mpleted Immedi coelled Immedi	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of take 1 tablet by oral route	2 times every day very 6 hours as needed for pe very 6 hours as needed Diagnostic/Referral Orders Ordered By	
PITOR ELEBREX ELEBREX YOROCODONE-ACETAMINOPHEN YOROCODONE-ACETAMINOPHEN Internal Allergies (Double-click to Bergy Date O KNOWN DRUG 01/1	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE O Add/Edit)	Referrals	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg situs Prionity ained Routine furmed immediangleted immedia	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of take 1 tablet by oral route	2 times every day very 6 hours as needed for pe very 8 hours as needed	
PITOR ELEBREX ELEBREX POROCODONE-ACETAMNOPHEN POROCODONE-ACETAMNOPHEN POROCODONE-ACETAMNOPHEN POROCODONE-ACETAMNOPHEN DITOR POROCODONE-ACETAMNOPHEN ONOVIVI DRUG ONOVIVI DRUG O1/11	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE HYDROCODONE O Add/Edit) of Onset 0/2013	Referrals	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg 10 mg-300 mg Itus Priority ained Routne mpleted Immedi coelled Immedi	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of take 1 tablet by oral route	2 times every day very 6 hours as needed for pe very 8 hours as needed	
PITOR CELEBREX CELEBREX HYDROCODONE-ACETAMINOPHEN HYDROCODONE-ACETAMINOPHEN Unrent Allergies (Double-click to Alergy Date NO KNOWN DRUG ALLERGES (Allergies reviewed/updated toda)	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE HYDROCODONE Adds/Edit) of Onset 0/2013	Referrals Ordered Sta 05:04:2015 000 07:20:2015 000 07:20:2015 000 07:20:2015 000	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg 10 mg-300 mg into Priority ained Routine Routine Immediated Immedi	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of tablet 1 tablet 1 tablet by oral route of tablet 1 ta	2 times every day very 6 hours as needed for pe very 6 hours as needed Diagnostic/Referral Orders Ordered By	
NO KNOWN DRUG 01/1 ALLERGES	CELECOXIB CELECOXIB HYDROCODONE HYDROCODONE HYDROCODONE Adds/Edit) of Onset 0/2013	Referrals Ordered Sta 05:04:2015 000 07:20:2015 000 07:20:2015 000 07:20:2015 000	50 mg 5 mg-500 mg 10 mg-300 mg 10 mg-300 mg 10 mg-300 mg into Priority ained Routine Routine Immediated Immedi	take 2 capsule by oral route take 2 capsule by oral route take 1 tablet by oral route of take 1 tablet by oral route	2 times every day very 6 hours as needed for pe very 8 hours as needed Disgnostic/Referral Orders Ordered By	

The CCM requires the patient to have at least two chronic conditions and documentation for each condition being tracked is required. The following is taken from the above template and shows what conditions are being tracked. The example used is outlined in green and shows that this patient is being "tracked" for diabetes.



When the Diabetes button outlined in green above is clicked the following pick list will be deployed: This allows the person calling the patient to efficiently document concerns the patient has with their care for the chronic condition involved.



There are seven structured data fields for Chronic Conditions for SETMA's deployment of the CCM function; they are:

- 1. Cardiac Disease
- 2. CHF
- 3. Depression
- 4. Diabetes
- 5. COPD/Asthma
- 6. Hyperlipdemia
- 7. Hypertension

There are several non-designated fields to be used for other chronic conditions.

When completed, each Tracked Problem will have a CCM template similar to the one below for diabetes. When the Diabetes tab above is clicked the CCM tool shown below will be deployed. For diabetes, there will be a HbA1c target with a date for that being achieved. The last three HbA1c will be document automatically. The Diabetes Consortium Data Set which includes targeted goals will be listed as is seen below and a referral tool will be deployable from this template as well.


In addition, there is a place to document the patient's expressed concerns about their diabetes care and a place to denote whether diabetes was discussed in the current CCM contact with the details of the discussion and the treatment plan.

racked Dia	betes Diagnose	3				Return
Primary	Diabetes 1.5, m	anaged as typ	pe 2			50
Secondary	Controlled type	2 diabetes wi	ith renal ma	nifestatio		
	Chronic kidney	disease, stage	e II (mild)			
			HbA1c H	istory		
Tar	get HbA1c 6	5	5.7	06/15/2015	Diabetes Consortium Data Set	
130	Date 09/14/2	15	5.7	06/15/2015		
1000	Committee of the Commit	the same of the sa				
Patient concer	cerns Related to	uture visits until		Addressed Today?	Diagnostic/Referral Orders Discussion/Plan	_
Patient concer Follow-up V	ms copy forward to f visit - When is my r	uture visits until ext appointme	of changed.	Addressed Today?	Discussion/Plan Scheduled appt for next tuesday with PCP	
Patient concer Follow-up V	ms copy forward to f	uture visits until ext appointme	of changed.	Addressed Today?	Discussion/Plan	12
Patient concer Follow-up V	ms copy forward to f visit - When is my r	uture visits until ext appointme	of changed.	Addressed Today? Y N Y N Y N	Discussion/Plan Scheduled appt for next tuesday with PCP	
Patient concer Follow-up V	ms copy forward to f visit - When is my r	uture visits until ext appointme	of changed.	Addressed Today? YON YON YON YON YON	Discussion/Plan Scheduled appt for next tuesday with PCP	
Patient concer Follow-up V Medications	ris copy forward to f risit - When is my r - Can I change my	uture visits until ext appointme	of changed.	Addressed Today? Y N Y N Y N	Discussion/Plan Scheduled appt for next tuesday with PCP	
Patient concer Follow-up V	ris copy forward to f risit - When is my r - Can I change my	uture visits until ext appointme	of changed.	Addressed Today? YON YON YON YON YON	Discussion/Plan Scheduled appt for next tuesday with PCP	
Patient concer Follow-up V Medications	ris copy forward to f risit - When is my r - Can I change my	uture visits until ext appointme	of changed.	Addressed Today? YON YON YON YON YON	Discussion/Plan Scheduled appt for next tuesday with PCP	
Patient concer Follow-up V Medications	ris copy forward to f risit - When is my r - Can I change my	uture visits until ext appointme	of changed.	Addressed Today? YON YON YON YON YON	Discussion/Plan Scheduled appt for next tuesday with PCP	

Time Tracking

Each patient enrolled in the CCM program must have a monthly contact. Between the planning and actually telephone contract the provider or nurse must spend at least twenty minutes to meet the requirement for a CCM payment. The following tools allow SETMA providers to document who completed the planning and who made the contract.





It is expected that the CCM program will decrease hospital admission and re-admissions and that it will improve patient health as it increases patient activation, engagement and shared decision making.